Orphan Drugs 2020
Sponsors & Exhibitors
EVERSANA is the leading independent provider of global services to the life science industry. From industry-leading patient service and adherence support to global pricing and revenue management, EVERSANA creates value across the life cycle for patients, prescribers, channel partners and payers. To learn more about EVERSANA, visit eversana.com.
Volv is a Digital Health & Life-Sciences company based in Switzerland. Using advanced and proprietary approaches, Volv creates new digital biomarkers that are highly predictive of diseases and from that helps create decision support tools for clinicians that can help them find and diagnose patients with ultra rare and difficult to diagnose conditions. Volv has been creating breakthrough capabilities to help design a digital medicine that will intervene and treat a really important disease in a novel and unique way. Volv will also announce some new digital diagnostics in the neurological and cognitive area.
Pulse Infoframe Inc (Pulse) believes that collaboration
cures disease and Pulse enables such collaboration. A new style of healthcare
informatics company, Pulsebuilds and supports global, healthcare ecosystems.
It’s solution, healthie™, empowers consortia of pharmaceutical and medical
device companies, researchers, clinicians, advocacy groups and patients, by
aggregating information from a variety of sources and then, delivering key
healthcare insights – real time -- derived from these data. For patients with
rare diseases, Pulse’s global coverage is critical. Already great strides have
been made in characterizing rare diseases using Pulse’s global and national
registries. These insights help professionals to advance medical research,
focus clinical trial recruitment, assist advocacy groups in their dealings with
policy makers and provide real-world evidence.
Illingworth Research Group is a provider of patient centric clinical research solutions. Services are tailored to clinical requirements but can include: mobile research nursing, patient concierge and medical photography, for example. These services are operational in 45 countries and concentrate on taking the trail to the patient or making trial participation easier and more accessible to patients and their families.
Patient centricity is a vital part of our mission and has been so for 20 years. Our Research Nursing support focuses on bringing the trial to the patient in their home, school or workplace. This can enhance both patient recruitment and retention. Our medical photography team offer an alternative approach by using imagery and video footage within the clinical trial. Imagery can be used in a range of applications concentrated within but not exclusive to dermatological trials.
Durbin is one of the leading providers of comparator sourcing and managed access programs to pharmaceutical and biotech companies around the world. In its 55th year of business, Durbin is pleased to look back on a history of sourcing pharmaceuticals for physicians and patients around the world and even in 3rd world countries, providing urgent and cost effective supply of pharmaceuticals to global charity and relief organizations and of course its pharmaceutical services division who source and distribute comparator drugs for clinical trials and run managed access programs that provide access to needed pharmaceuticals in non-approved markets. Durbin’s distribution network includes regular shipments to over 180 countries globally. Their managed access programs include orphan, gene, and controlled products. Durbin has full service offices in the United Kingdom, European Union and United States.
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. Mastermind Genomic Landscapes inform pharmaceutical companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named Company of the Year in Clinical Genomics Interpretation 2020 by Frost & Sullivan.